BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL

被引：0
|
作者：
Asano, E. [1 ]
Nita, M. [1 ]
Moellmann-Coelho, A. [2 ]
Rached, R. [1 ]
Donato, B. [3 ]
Rahal, E. [1 ]
机构：
[1] Bristol Myers Squibb SA, Sao Paulo, Brazil
[2] Inst Nacl Canc INCA, Rio De Janeiro, Brazil
[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74285-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A262 / A262
页数：1
相关论文
共 50 条
  • [41] Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
    O Frank
    B Brors
    A Fabarius
    L Li
    M Haak
    S Merk
    U Schwindel
    C Zheng
    M C Müller
    N Gretz
    R Hehlmann
    A Hochhaus
    W Seifarth
    Leukemia, 2006, 20 : 1400 - 1407
  • [42] Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
    Valent, Peter
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04): : 433 - 448
  • [43] Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients
    Celik, Selcen
    Akcora, Dilara
    Ozkan, Tulin
    Varol, Nuray
    Aydos, Sena
    Sunguroglu, Asuman
    ONCOLOGY LETTERS, 2015, 9 (01) : 399 - 404
  • [44] Management of imatinib-resistant CML patients
    Linke, Rolf
    Dempke, Wolfram
    ONKOLOGIE, 2007, 30 (11): : 574 - 580
  • [45] Differential Effects of Imatinib and Dasatinib On Immune Effector Cells in Patients with Chronic Myeloid Leukemia (CML)
    Rohon, Peter
    Porkka, Kimmo
    Mustjoki, Satu
    BLOOD, 2009, 114 (22) : 1272 - 1272
  • [46] NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Koren-Michowitz, M. K. M.
    Le Coutre, P.
    Duyster, J.
    Scheid, C.
    Rowe, J. M.
    Goldschmidt, N.
    Ribakovsky, E.
    Nagler, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 222 - 223
  • [47] Dasatinib Induces Significant Hematologic and Cytogenetic Responses in Patients with Imatinib-resistant or-intolerant Chronic Myeloid Leukemia in Accelerated Phase
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (04) : 23 - U24
  • [48] An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China A CHEERS-compliant article
    Wu, Bin
    Liu, Maobai
    Li, Te
    Lin, Houwen
    Zhong, Hua
    MEDICINE, 2017, 96 (29)
  • [49] The cost and cost effectiveness of dasatinib (Sprycel) therapy for the management of imatinib resistant and intolerant patients with chronic myeloid leukemia (CML) in Mexico
    Juarez-Garcia, A.
    Zapata, L.
    Vega, G.
    Idrovo, J.
    Rivas, R.
    Kramis, J. L.
    Litalien, G.
    Rangel, S.
    VALUE IN HEALTH, 2008, 11 (03) : A157 - A157
  • [50] The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
    Zhu, Yu
    Pan, Liangqin
    Hong, Ming
    Liu, Weixing
    Qiao, Chun
    Li, Jianyong
    Qian, Sixuan
    JOURNAL OF BIOMEDICAL RESEARCH, 2016, 30 (06): : 525 - 528
12345